Literature DB >> 10325327

Development of a simple and highly sensitive enzyme immunoassay for hepatitis C virus core antigen.

K Aoyagi1, C Ohue, K Iida, T Kimura, E Tanaka, K Kiyosawa, S Yagi.   

Abstract

A highly sensitive enzyme immunoassay (EIA) for the hepatitis C virus (HCV) core antigen (HCVcAg) was developed, and its performance was compared with that of the AMPLICOR HCV test (Roche Molecular Systems). The developed one-step pretreatment method, 30-min incubation of the specimen with a solution containing three different types of detergents (Triton X-100, 3-[(3-cholamidopropyl)-dimethylammonio]-1-propanesulfonate [CHAPS], and sodium dodecyl sulfate), does not require any special device. Because the interfering anti-core antibody in the sample was sufficiently inactivated by the pretreatment, HCVcAg in the sample could be detected. The immunoreactivity on gel filtration was shifted from void fractions to those corresponding to the molecular mass range from 20 to 25 kDa, which is equal to the estimated molecular mass of HCVcAg, after the pretreatment. By the recovery test with HCVcAg-positive serum, the recovery rate was 93.5 to 106. 5%. There was no interference with the EIA by anticoagulants or blood components in the serum. When the cutoff value was tentatively set at 0.5 mU/ml based on the distribution of healthy subjects' sera, the sera of all healthy subjects (n = 125) and patients with hepatitis B (n = 50) were negative. HCVcAg was detected in sera from 57 of 73 individuals (78.1%) with anti-HCV antibody. Similarly, HCV RNA was detected in sera from 59 individuals (80.8%) with the AMPLICOR HCV as the qualitative test (AMPLICOR HCV test) and in sera from 54 individuals (74.0%) by the AMPLICOR HCV Monitor as the quantitative test (AMPLICOR Monitor test). Concentrations of HCVcAg and HCV RNA (measured by the AMPLICOR Monitor test) correlated significantly (r = 0.8, P < 0.001). On seroconversion panels, HCVcAg was detected during the early stage of infection, when anti-HCV antibodies had not been produced. This assay for HCVcAg is simpler than assays for HCV RNA based on gene technology and shows specificity and sensitivity equivalent to those of the AMPLICOR HCV test.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10325327      PMCID: PMC84955     

Source DB:  PubMed          Journal:  J Clin Microbiol        ISSN: 0095-1137            Impact factor:   5.948


  38 in total

1.  Continuous cultures of fused cells secreting antibody of predefined specificity.

Authors:  G Köhler; C Milstein
Journal:  Nature       Date:  1975-08-07       Impact factor: 49.962

2.  Isolation of a cDNA clone derived from a blood-borne non-A, non-B viral hepatitis genome.

Authors:  Q L Choo; G Kuo; A J Weiner; L R Overby; D W Bradley; M Houghton
Journal:  Science       Date:  1989-04-21       Impact factor: 47.728

3.  Gene mapping of the putative structural region of the hepatitis C virus genome by in vitro processing analysis.

Authors:  M Hijikata; N Kato; Y Ootsuyama; M Nakagawa; K Shimotohno
Journal:  Proc Natl Acad Sci U S A       Date:  1991-07-01       Impact factor: 11.205

Review 4.  Molecular biology of the hepatitis C viruses: implications for diagnosis, development and control of viral disease.

Authors:  M Houghton; A Weiner; J Han; G Kuo; Q L Choo
Journal:  Hepatology       Date:  1991-08       Impact factor: 17.425

5.  Interference of heparin with the polymerase chain reaction.

Authors:  E Beutler; T Gelbart; W Kuhl
Journal:  Biotechniques       Date:  1990-08       Impact factor: 1.993

6.  Detection of antibody against antigen expressed by molecularly cloned hepatitis C virus cDNA: application to diagnosis and blood screening for posttransfusion hepatitis.

Authors:  T Miyamura; I Saito; T Katayama; S Kikuchi; A Tateda; M Houghton; Q L Choo; G Kuo
Journal:  Proc Natl Acad Sci U S A       Date:  1990-02       Impact factor: 11.205

7.  Evaluation of the automated COBAS AMPLICOR hepatitis C virus PCR system.

Authors:  M Poljak; K Seme; S Koren
Journal:  J Clin Microbiol       Date:  1997-11       Impact factor: 5.948

8.  An assay for circulating antibodies to a major etiologic virus of human non-A, non-B hepatitis.

Authors:  G Kuo; Q L Choo; H J Alter; G L Gitnick; A G Redeker; R H Purcell; T Miyamura; J L Dienstag; M J Alter; C E Stevens
Journal:  Science       Date:  1989-04-21       Impact factor: 47.728

9.  Demonstration of a hepatitis C virus-specific antigen predicted from the putative core gene in the circulation of infected hosts.

Authors:  K Takahashi; H Okamoto; S Kishimoto; E Munekata; K Tachibana; Y Akahane; H Yoshizawa; S Mishiro
Journal:  J Gen Virol       Date:  1992-03       Impact factor: 3.891

10.  Typing hepatitis C virus by polymerase chain reaction with type-specific primers: application to clinical surveys and tracing infectious sources.

Authors:  H Okamoto; Y Sugiyama; S Okada; K Kurai; Y Akahane; Y Sugai; T Tanaka; K Sato; F Tsuda; Y Miyakawa
Journal:  J Gen Virol       Date:  1992-03       Impact factor: 3.891

View more
  51 in total

1.  Endocytosis of hepatitis C virus non-enveloped capsid-like particles induces MAPK-ERK1/2 signaling events.

Authors:  Konstantina Katsarou; Alexandros Alpha Lavdas; Panagiota Tsitoura; Elisavet Serti; Panagiotis Markoulatos; Penelope Mavromara; Urania Georgopoulou
Journal:  Cell Mol Life Sci       Date:  2010-04-01       Impact factor: 9.261

2.  Oligomerization of hepatitis C virus core protein is crucial for interaction with the cytoplasmic domain of E1 envelope protein.

Authors:  Kousuke Nakai; Toru Okamoto; Tomomi Kimura-Someya; Koji Ishii; Chang Kweng Lim; Hideki Tani; Eiko Matsuo; Takayuki Abe; Yoshio Mori; Tetsuro Suzuki; Tatsuo Miyamura; Jack H Nunberg; Kohji Moriishi; Yoshiharu Matsuura
Journal:  J Virol       Date:  2006-09-13       Impact factor: 5.103

3.  Monitoring treatment response by the hepatitis C virus core antigen assay.

Authors:  M Lindh; M Lagging; J Westin; R Wejstål; G Norkrans
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2005-03       Impact factor: 3.267

4.  Evaluation of hepatitis C virus core antigen assays in detecting recombinant viral antigens of various genotypes.

Authors:  Mohsan Saeed; Ryosuke Suzuki; Madoka Kondo; Hideki Aizaki; Takanobu Kato; Toshiaki Mizuochi; Takaji Wakita; Haruo Watanabe; Tetsuro Suzuki
Journal:  J Clin Microbiol       Date:  2009-10-07       Impact factor: 5.948

5.  Proteasome activator PA28gamma-dependent nuclear retention and degradation of hepatitis C virus core protein.

Authors:  Kohji Moriishi; Tamaki Okabayashi; Kousuke Nakai; Kyoji Moriya; Kazuhiko Koike; Shigeo Murata; Tomoki Chiba; Keiji Tanaka; Ryosuke Suzuki; Tetsuro Suzuki; Tatsuo Miyamura; Yoshiharu Matsuura
Journal:  J Virol       Date:  2003-10       Impact factor: 5.103

6.  New enzyme immunoassay for detection of hepatitis B virus core antigen (HBcAg) and relation between levels of HBcAg and HBV DNA.

Authors:  Tatsuji Kimura; Akinori Rokuhara; Akihiro Matsumoto; Shintaro Yagi; Eiji Tanaka; Kendo Kiyosawa; Noboru Maki
Journal:  J Clin Microbiol       Date:  2003-05       Impact factor: 5.948

7.  Comparative evaluation of the total hepatitis C virus core antigen, branched-DNA, and amplicor monitor assays in determining viremia for patients with chronic hepatitis C during interferon plus ribavirin combination therapy.

Authors:  Pascal Veillon; Christopher Payan; Gastón Picchio; Michèle Maniez-Montreuil; Philippe Guntz; Françoise Lunel
Journal:  J Clin Microbiol       Date:  2003-07       Impact factor: 5.948

8.  Non-enveloped HCV core protein as constitutive antigen of cold-precipitable immune complexes in type II mixed cryoglobulinaemia.

Authors:  D Sansonno; G Lauletta; L Nisi; P Gatti; F Pesola; N Pansini; F Dammacco
Journal:  Clin Exp Immunol       Date:  2003-08       Impact factor: 4.330

9.  Stable replication of the EBNA1/OriP-mediated baculovirus vector and its application to anti-HCV gene therapy.

Authors:  Hitoshi Suzuki; Norihiko Matsumoto; Tomoyuki Suzuki; Myint Oo Chang; Hiroshi Takaku
Journal:  Virol J       Date:  2009-10-02       Impact factor: 4.099

Review 10.  Human immunodeficiency virus: 25 years of diagnostic and therapeutic strategies and their impact on hepatitis B and C virus.

Authors:  Martin Stürmer; Hans Wilhelm Doerr; Lutz Gürtler
Journal:  Med Microbiol Immunol       Date:  2009-06-04       Impact factor: 3.402

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.